Recently, agents targeting the PD1/PD-L1 pathway have demonstrated efficacy as single agents and in combination with other therapies and may eventually play a prominent role in the management of patients with kidney cancer 4-6. This evidence concerns the gene PDCD1 and kidney cancer.